



Commonwealth of Massachusetts
MassHealth Drug Utilization Review Program
 P.O. Box 2586, Worcester, MA 01613-2586
Fax: (877) 208-7428 **Phone:** (800) 745-7318

Opioid Dependence and Reversal Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Member information

Last name _____ First name _____ MI _____
 MassHealth member ID # _____ Date of birth _____
 Gender (Check one.) F M Member's place of residence home nursing facility

Medication information

Medication requested

- | | | | |
|--|---|---|---|
| <input type="checkbox"/> Bunavail (buprenorphine/naloxone buccal film) | <input type="checkbox"/> 2.1 mg/0.3 mg | <input type="checkbox"/> 4.2 mg/0.7 mg | <input type="checkbox"/> 6.3 mg/1 mg |
| <input type="checkbox"/> buprenorphine tablet | <input type="checkbox"/> 2 mg | <input type="checkbox"/> 8 mg | |
| <input type="checkbox"/> buprenorphine/naloxone film | <input type="checkbox"/> 2 mg/0.5 mg | <input type="checkbox"/> 4 mg/1 mg | <input type="checkbox"/> 8 mg/2 mg |
| | <input type="checkbox"/> 12 mg/3 mg | | |
| <input type="checkbox"/> buprenorphine/naloxone tablet | <input type="checkbox"/> 2 mg/0.5 mg | <input type="checkbox"/> 8 mg/2 mg | |
| <input type="checkbox"/> Kloxxado (naloxone 8 mg nasal spray) | | | |
| <input type="checkbox"/> Lucemyra (lofexidine) | | | |
| <input type="checkbox"/> Probuphine (buprenorphine implant) | | | |
| <input type="checkbox"/> Zubsolv (buprenorphine/naloxone tablet) | <input type="checkbox"/> 0.7 mg/0.18 mg | <input type="checkbox"/> 1.4 mg/0.36 mg | <input type="checkbox"/> 2.9 mg/0.71 mg |
| | <input type="checkbox"/> 5.7 mg/1.4 mg | <input type="checkbox"/> 8.6 mg/2.1 mg | <input type="checkbox"/> 11.4 mg/2.9 mg |

Dose, frequency, and duration of medication requested _____

For all requests for medications containing buprenorphine, is the member maintained on the lowest effective dose?

Yes No. If no, please provide complete treatment plan. _____

Indication (Check all that apply.)

Management of opioid withdrawal symptoms Opioid dependence Other _____

Section I. Please complete for all requests.

- Please indicate billing preference. Pharmacy Prescriber in-office Hospital outpatient
 For hospital outpatient billing, provide department-specific facility NPI _____
- Drug NDC (if known) or service code _____
- Has the prescriber evaluated the Massachusetts Prescription Awareness Tool (MassPAT) data? Yes No

4. Is this member a referral candidate for care coordination? Yes No

If yes, MassHealth will offer this member care coordination services. Please describe which additional behavioral health services would be beneficial.

Section II. Please complete for buprenorphine tablet requests.

1. Is the member pregnant? Yes. Anticipated date of delivery _____ No

2. Is the member breastfeeding? Yes No

3. Does the member have a documented allergy to naloxone? Yes No

If yes, please provide medical records documenting the allergic reaction.

4. If you answered "No" to the three questions above, please provide medical necessity for prescribing buprenorphine rather than buprenorphine/naloxone. (Please explain below and provide medical records.)

Section III. Please complete for buprenorphine, buprenorphine/naloxone film, and buprenorphine/naloxone tablet doses exceeding 24 mg/day, Bunavail doses exceeding 12.6 mg/day, and Zubsolv doses exceeding 17.2 mg/day.

Please document medical necessity for high dose of buprenorphine/naloxone and buprenorphine below and submit medical records supporting the medical necessity provided.

Section IV. Please complete for Bunavail, buprenorphine/naloxone tablets, and Zubsolv requests.

Has the member had an allergic reaction to buprenorphine/naloxone film?

Yes. (Specify and provide medical records.)

No. Please explain.

Section V. Please complete for Probuphine requests.

1. Is the member currently stabilized on ≤ 8 mg buprenorphine or equivalent dosed formulation for at least six months? Yes No

2. Please describe medical necessity for use of the implanted formulation.

3. Please attach medical records documenting an allergic reaction, contraindication, or inadequate response to all other clinically appropriate therapeutic alternatives.

Section VI. Please complete for Lucemyra requests.

Has the member had a trial with oral clonidine?

Yes. Please list the dose and frequency, dates/durations of use, and outcomes below.

Dose and frequency _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please describe clinical rationale why the member is not a candidate for oral clonidine.

Section VII. Please complete for Kloxxado requests.

Has the member had a trial with Narcan?

Yes. Please list the dose and frequency, dates/durations of use, and outcomes below.

Dose and frequency _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Other

Briefly describe details of adverse reaction, contraindication, or other.

No. Please describe clinical rationale for use of the requested agent instead of other naloxone alternatives.

Section VIII. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

Prescriber information

Last name* _____ First name* _____ MI _____

NPI* _____ Individual MH Provider ID _____

DEA No. _____ Office Contact Name _____

Address _____ City _____ State _____ Zip _____

E-mail address _____

Telephone No.* _____ Fax No.* _____

* *Required*

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

Signature required _____

Printed name of prescribing provider _____ Date _____